Search Result

Results for "

G0/G1 phase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (1) Akt (5) Antibiotic (2) Apoptosis (61) Autophagy (5) Bacterial (2) Bcl-2 Family (1) Bcr-Abl (2) c-Kit (1) c-Met/HGFR (3) Carbonic Anhydrase (1) Caspase (1) CDK (3) Deubiquitinase (1) Dihydrofolate reductase (DHFR) (2) DNA Methyltransferase (2) EGFR (7) Endogenous Metabolite (2) Epigenetic Reader Domain (4) Estrogen Receptor/ERR (3) FAK (1) FGFR (1) FLT3 (4) GLUT (1) HDAC (6) Histone Acetyltransferase (1) Histone Demethylase (1) Histone Methyltransferase (1) HMG-CoA Reductase (HMGCR) (2) HSP (2) JAK (1) JNK (1) LXR (1) MDM-2/p53 (1) MNK (1) mTOR (2) NF-κB (1) PAK (2) PARP (2) PD-1/PD-L1 (1) PDGFR (1) Phosphodiesterase (PDE) (1) PI3K (3) PROTACs (1) Raf (2) Ras (1) Reactive Oxygen Species (5) SHP2 (1) Sigma Receptor (1) Topoisomerase (4) Trk Receptor (2) VEGFR (1)
By Research Areas:	Cancer (82) Cardiovascular Disease (4) Infection (2) Inflammation/Immunology (3) Metabolic Disease (2) Neurological Disease (3)
Click Chemistry:	Azide (1)

Inhibitors & Agonists

Peptides

Natural
Products

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13680

Meisoindigo Dian III; N-Methylisoindigotin; Natura-α	Apoptosis	Cancer
Meisoindigo (Dian III), a derivative of Indirubin (HY-N0117), halts the cell cycle at the G0/G1 phase and induces apoptosis in primary acute myeloid leukemia (AML) cells. Meisoindigo exhibits high antitumor activity .

HY-152245

Physachenolide C	Epigenetic Reader Domain	Cancer
Physachenolide C is a potent and selective BET inhibitor that induces apoptosis and arrests the cell cycle in the G0-G1 phase, with antitumor activity .

HY-124261

Sampangine	Apoptosis	Cancer
Sampangine is an alkaloid that induces apoptosis by inducing cell cycle arrest in the G0/G1 phase. Sampangine can inhibit the biosynthesis of heme .

HY-155552

GSPT1 degrader-1	Apoptosis	Cancer
GSPT1 degrader-1 (compound 9q) is a potent degrader of G1 to S phase transition 1 (GSPT1) via ubiquitin-proteasome system. GSPT1 degrader-1 also induces cell G0/G1 phase arrest and apoptosis .

HY-13768C

Topotecan hydrochloride hydrate SKF 104864A hydrochloride hydrate; NSC 609669 hydrochloride hydrate	Topoisomerase Apoptosis Autophagy	Cancer
Topotecan hydrochloride hydrate is an orally active and potent Topoisomerase I inhibitor. Topotecan hydrochloride hydrate induces cell cycle arrest in G0/G1 and S phases and promotes apoptosis. Topotecan hydrochloride hydrate shows anticancer activity .

HY-13768

Topotecan SKF 104864A; NSC 609669	Topoisomerase Autophagy Apoptosis	Cancer
Topotecan (SKF 104864A; NSC 609669) is an orally active and potent Topoisomerase I inhibitor. Topotecan induces cell cycle arrest in G0/G1 and S phases and promotes apoptosis. Topotecan shows anticancer activity .

HY-162416

CDK7-IN-27	CDK	Cancer
CDK7-IN-27 (Compound 37) is a selective inhibitor for cyclin-dependent kinase 7 (CDK7), with K_i of 3 nM. CDK7-IN-27 arrests the cell cycle at G0/G1 phase .

HY-155544

Antitumor agent-111	c-Met/HGFR	Cancer
Antitumor agent-111 (compound 46) is an c-Met kinase inhibitor (IC₅₀=46 nM) with antitumor and antiproliferative activity. Antitumor agent-111 arrests cell cycle at G0/G1 phase, and induces apoptosis .

HY-155503

Antitumor agent-103	Apoptosis	Cancer
Antitumor agent-103 (compound 24l) is an apoptosis inducer with antiproliferative and anti-clony formation activities. Antitumor agent-103 arrests cell cycle at G0/G1 phase, enhances NO production, and exhibits anti-tumor activity .

HY-147801

Topoisomerase IIα-IN-3	Topoisomerase Apoptosis	Cancer
Topoisomerase IIα-IN-3 (Compound 12c) is a DNA intercalative topoisomerase-IIα inhibitor. Topoisomerase IIα-IN-3 arrests cell cycle at the G0/G1 phase and induces apoptosis .

HY-145762

YM281	Apoptosis Histone Methyltransferase	Cancer
YM281 is a potent EZH2 inhibitor. YM281 induces cell apoptosis and cell cycle arrest at the G0/G1 phase. YM281 shows antitumor effects in vivo. YM281 has the potential for the research of lymphoma .

HY-149063

Antitumor agent-92	Apoptosis	Cancer
Antitumor agent-92, an Icaritin (HY-N0678) derivative, causes arrest at the G0/G1 phase in the cell cycle and induces cell apoptosis. Antitumor agent-92 has the potential for hepatocellular carcinoma (HCC) research .

HY-144733

ERα antagonist 1	Estrogen Receptor/ERR Apoptosis	Cancer
ERα antagonist 1 (Compound 19d) is a potent, selective, covalent estrogen receptor α (ERα) antagonist. ERα antagonist 1 induces apoptosis and cell cycle G0/G1 phase arrest in MCF-7 cells .

HY-163722

EGFR/DHFR-IN-1	EGFR Dihydrofolate reductase (DHFR)	Cancer
EGFR/DHFR-IN-1 (Compound 10e) is a dual inhibitor of EGFR and DHFR with IC₅₀s of 0.151 and 0.541 µM, respectively. EGFR/DHFR-IN-1 arrests the cell cycle at both G0-G1 and S phases .

HY-159096

Apoptosis inducer 21	Apoptosis	Cancer
Apoptosis inducer 21 (Compound 5h) inhibits the proliferation of lung cancer cell H69AR with an IC₅₀ of 1.58 μM. Apoptosis inducer 21 arrests the cell cycle at G0/G1 phase, induces apoptosis in H69AR .

HY-146063

Anticancer agent 54	Apoptosis	Cancer
Anticancer agent 54 is a potent anticancer agent. Anticancer agent 54 shows antiproliferative activity. Anticancer agent 54 induces apoptosis and cell cycle arrest at G0/G1 phases. Anticancer agent 54 shows anticancer activity depends on DNA intercalation and ROS generation .

HY-146040

Anticancer agent 47	Apoptosis	Cancer
Anticancer agent 47 (compound 4j) is a potent anticancer agent. Anticancer agent 47 shows antiproliferative activities. Anticancer agent 47 induces apoptosis and cell cycle arrest at G0/G1 phase. Anticancer agent 47 shows shows antitumor activities in vivo .

HY-10638

AP23464	c-Kit Apoptosis	Cancer
AP23464 is an ATP-based inhibitor for Kit, that inhibits the phosphorylation of Kit wildtype and mutants, with IC₅₀ of 5-85 nM. AP23464 inhibits the proliferation of Kit mutated cells (IC₅₀ is 3-20 nM), arrests the cell cycle at G0/G1 phase, and induces apoptosis in Kit mutated cells .

HY-144394

Antitumor agent-45	Apoptosis c-Met/HGFR	Cancer
Antitumor agent-45 (Compound 21) could induce and stimulate A549 cells apoptosis in G0/G1 and G2/M phase. Antitumor agent-45 (Compound 21) inhibits c-Met expression to regulate the growth of tumor cells .

HY-W014940

Ethylene glycol dimethacrylate	Reactive Oxygen Species Apoptosis	Others
Ethylene glycol dimethacrylate is a methacrylate monomer, exhibits cytotoxic and genotoxic effects on human gingival fibroblasts (HGFs). Ethylene glycol dimethacrylate increases intracellular reactive oxygen species (ROS) production, causes DNA damage, increases apoptosis and causes cell cycle arrest in G1/G0 phase .

HY-129592

p-Tolylmaleimide	Apoptosis	Cancer
p-Tolylmaleimide (compound 9) is a naphthalimide derivative that has cytotoxic effects on cancer cells. p-Tolylmaleimide can arrest the cell cycle of human acute myeloid leukemia cells K562 in the sub-G0/G1 phase and induce apoptosis .

HY-165064

C2 L-Erythro ceramide (d18:1/2:0) L-Erythro cer(d18:1/2:0); N-Acetyl-L-erythro-sphingosine; Acetyl-L-erythro-sphingosine	Others	Cancer
C2 L-Erythro ceramide (d18:1/2:0) is a cell-permeable sphingolipid. C2 L-Erythro ceramide (d18:1/2:0) induces cell cycle arrest in the G0/G1 phase and inhibits cell growth .

HY-146203

FAK inhibitor 6	FAK	Cancer
Compound 26F not only optimized the effective inhibitory enzyme (ic₅₀= 28.2 nm), but also showed relatively less cytotoxicity (ic₅₀= 3.32 μ M) And induced MDA-MB-231 cell apoptosis in a dose-dependent manner, effectively blocking MDA-MB-231 cells in g0/g1 phase.

HY-143490

PAK4-IN-2	PAK Apoptosis	Cancer
PAK4-IN-2 is a highly potent PAK4 inhibitor with IC₅₀ value of 2.7 nM. PAK4-IN-2 can arrest MV4-11 cells at G0/G1 phase and induce cell apoptosis. PAK4-IN-2 can be used for researching cancer .

HY-146445

P300 bromodomain-IN-1	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
P300 bromodomain-IN-1 (Compoun 1u) is a potent p300 (EP300) bromodomain inhibitor with an IC₅₀ of 49 nM. P300 bromodomain-IN-1 suppresses the expression of c-Myc and induces G1/G0 phase arrest and apoptosis in OPM-2 cells .

HY-N7844

N6-Benzyladenosine Benzyladenosine	Apoptosis Adenosine Receptor	Inflammation/Immunology Cancer
N6-Benzyladenosine is an adenosine receptor agonist, has a cytoactive activity. N6-Benzyladenosine arrests cell cycle at G0/G1 phase and induces cell apoptosis. N6-Benzyladenosine also exerts inhibitory effect on T. gondii adenosine kinase and glioma ^- .

HY-N1930

(-)-Hinesol Hinesol	Apoptosis	Cancer
(-)-Hinesol (Hinesol) is a potent anticancer agent. (-)-Hinesol induces apoptosis and cell cycle arrest at G0/G1 phase. (-)-Hinesol downregulates MEK/ERK pathway and NF-κB pathway and mediates theexpression of cyclin D1, Bax and Bcl-2. (-)-Hinesol has the potential for the research of non–small cell lung cancer .

HY-W747572

(+)-Perillyl alcohol (R)-(+)-perillyl alcohol	Ras	Cancer
(+)-Perillyl alcohol is the enantiomer of S-(-)-Perillyl alcohol (HY-116514). (+)-Perillyl alcohol can inhibit the growth of polypeptides and block the cell cycle in the G0/G1 phase. (+)-Perillyl alcohol induces cell signaling that is associated with changes in cytoskeletal actin organization and reduced protein expression of growth regulatory proteins such as Ras and CDC2 kinase .

HY-159101

EP26	EGFR PD-1/PD-L1	Cancer
EP26 is a potent and orally active EGFR and PD-L1 inhibitor with IC₅₀ values of 48.6 nM, 1.77 µM, respectively. EP26 decreased the protein expression of p-EGFR. EP26 induces cell cycle arrest at G0/G1 phase. EP26 has the potential for the research of glioblastoma .

HY-146132

EGFR-IN-55	EGFR	Cancer
EGFR-IN-55 (Compound 8a) is a potent EGFR inhibitor with IC₅₀ values of 70 nM and 3.9 nM against EGFR ^WT and EGFR ^L858R/T790M, respectively. EGFR-IN-55 arrests NCI-H1975 cells in G0/G1 phase and shows anticancer activity .

HY-17408

Mevastatin 5+ Cited Publications Compactin; ML236B	HMG-CoA Reductase (HMGCR) Bacterial Autophagy Apoptosis Antibiotic	Infection Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Mevastatin (Compactin) is a first HMG-CoA reductase inhibitor that belongs to the statins class. Mevastatin is a lipid-lowering agent, and induces apoptosis, arrests cancer cells in G₀/G₁ phase. Mevastatin also increases endothelial nitric oxide synthase (eNOS) mRNA and protein levels. Mevastatin has antitumor activity and has the potential for cardiovascular diseases treatment .

HY-10815

σ1 Receptor antagonist-1 1 Publications Verification	Sigma Receptor Apoptosis	Neurological Disease Cancer
σ1 Receptor antagonist-1 is a highly potent and selective sigma 1 receptor antagonist (pK_i=10.28). σ1 Receptor antagonist-1 inhibits cell growth, arrests cell cycle at G0/G1 phase and induces apoptosis of MCF-7/ADR cells .

HY-120654

[1,1′:4′,1′′-Terphenyl]-3,4′′,5-triol	Apoptosis	Cancer
[1,1′:4′,1′′-Terphenyl]-3,4′′,5-triol (compound 13g) is a terphenyl derivative that blocks the cell cycle in the G0-G1 phase and induces differentiation in leukemia cells. [1,1′:4′,1′′-Terphenyl]-3,4′′,5-triol shows a potent apoptotic effect .

HY-162755

SHP2-IN-30	SHP2 Apoptosis	Cancer
SHP2-IN-30 (compound 14i) is an allosteric SHP2 inhibitor with an IC₅₀ of 104 nM. SHP2-IN-30 shows low inhibitory effect on SHP2-PTP. SHP2-IN-30 induces cell apoptosis and arrests the cell cycle at the G0/G1 phase .

HY-149891

HSP90-IN-23	HSP	Cancer
HSP90-IN-23 (Comp 12-1) is an inhibitor of heat shock protein 90(HSP90) with an IC₅₀ of 9 nM. HSP90-IN-23 induces apoptosis of tumor cells and arrests the tumor cell cycle in G0/G1 phase. HSP90-IN-23 can be used for cancer research .

HY-N12044

Asparanin A	Apoptosis	Cancer
Asparanin A is an apoptosis inducer with anticancer activity. Asparanin A induces cell cycle arrest in the G0/G1 phase through mitochondria and PI3K/AKT signaling pathways, inhibiting cancer cell growth. Asparanin A also demonstrated in vivo efficacy in a mouse xenograft model of Ishikawa endometrial carcinoma, significantly inhibiting tumor growth .

HY-110293

CHMFL-FLT3-122	FLT3 Apoptosis	Cancer
CHMFL-FLT3-122 is a potent, selective and orally active FLT3 kinase with an IC₅₀ of 40 nM. CHMFL-FLT3-122 shows selectivity for FLT3 over BTK (IC₅₀ of 421 nM) and c-KIT (IC₅₀ of 559 nM) kinases. CHMFL-FLT3-122 induces apoptosis by arresting the cell cycle into the G0/G1 phase .

HY-15221

Methylstat 1 Publications Verification	Apoptosis Histone Demethylase MDM-2/p53	Cardiovascular Disease Cancer
Methylstat is a potent histone demethylases inhibitor. Methylstat shows anti-proliferative activity with low cytotoxicity. Methylstat induces apoptosis and cell cycle arrest at G0/G1 phase. Methylstat increases the expression of p53 and p21 protein levels. Methylstat inhibits angiogenesis induced by various cytokines. Methylstat can be used as a chemical probe for addressing its role in angiogenesis .

HY-149735

BET-IN-20	Epigenetic Reader Domain Apoptosis	Cancer
BET-IN-20 (compound 10) is an inhibitor of BRD4 BD1 (IC₅₀=1.9 nM) with anticancer activity. BET-IN-20 can promote acute myeloid leukemia (AML) cell apoptosis and arrest the cell cycle in the G0/G1 phase. BET-IN-20 also inhibits c-Myc and CDK6 and enhances PARP cleavage .

HY-122359A

rel-Levormeloxifene rel-L-Centchroman; Ormeloxifene	Estrogen Receptor/ERR Apoptosis Reactive Oxygen Species	Cancer
rel-Levormeloxifene (rel-L-Centchroman) is the relative configuration of Levormeloxifene (HY-122359). rel-Levormeloxifene is a selective estrogen receptor modulator (SERM). rel-Levormeloxifene inhibits proliferation of leukemia cells with IC₅₀ about 7 μM, arrests cell cycle at G0/G1 phase, and induces apoptosis. rel-Levormeloxifene induces differentation of myelogenesis leukemia, and enhances ROS production in K562 cells .

HY-162868

c-Met/HDAC-IN-4	c-Met/HGFR HDAC Apoptosis	Cancer
c-Met/HDAC-IN-4 is a dual inhibitor of c-Met/HDAC. The IC₅₀ value of c-Met/HDAC-IN-4 for c-Met is 28.92 nM. c-Met/HDAC-IN-4 can induce G₀/G₁ phase cell cycle arrest and apoptosis in MDA-MB-231 breast cancer cells, and it inhibits the proliferation and invasion of breast cancer cell lines .

HY-156453

PAK4-IN-3	PAK Apoptosis	Cancer
PAK4-IN-3(compound 27e) is aPAK4inhibitor, with theIC₅₀of 10 nM.PAK4-IN-3shows antiproliferative activity against A549 cells with anIC₅₀value of 0.61μM, and inducesapoptosisof A549 cells in a concentration-dependent manner and blocked the cell cycle at phase G0/G1 .

HY-157814

Menin-MLL inhibitor-25	Apoptosis Epigenetic Reader Domain	Cancer
Menin-MLL inhibitor-25 (compound A6) is a potent Menin-MLL interaction inhibitor with an IC₅₀ value of 0.38 µM. Menin-MLL inhibitor-25 shows anti-proliferative activity. Menin-MLL inhibitor-25 induces apoptosis and cell cycle arrest at G0/G1 phase. Menin-MLL inhibitor-25 reverses the differentiation arrest .

HY-163535

J208	HDAC DNA Methyltransferase Apoptosis	Inflammation/Immunology Cancer
J208 is a dual inhibitor for histone deacetylase (HDAC) and DNA methyltransferase (DNMT). J208 inhibits proliferation of cancer cells, as well as the migration/invasion of triple-negative breast cancer (TNBC) cells. J208 induces apoptosis, arrests the cell cycle at G0/G1 phase. J2008 activates the innate immune signalling pathway in TNBC, by inducing the expression of endogenous retroviruses (ERVs) .

HY-147935

NTQ1062	Akt	Cancer
NTQ1062 is a potent and orally active Akt inhibitor with IC₅₀s of 0.4 nM, 6.3 nM and 0.1 nM for Akt1, Akt2 and Akt3, respectively. NTQ1062 induces cell apoptosis and arrests the cell cycle at G0/G1 phase. NTQ1062 exhibits antiproliferation activity against various cancer cells. NTQ1062 exhibits potent antitumor efficacy in LNCap xenograft mouse model .

HY-123486

HS-438	Apoptosis Bcr-Abl	Cancer
HS-438 is a potent and selective BCR-ABL inhibitor. HS-438 shows antiproliferative activity. HS-438 decreases the expression of phosphorylation of BCR-ABL (Tyr177). HS-438 induces apoptosis and cell cycle arrest at G0/G1 phase. HS-438 shows antitumor activity. HS-438 has the potential for the research of chronic myeloid leukemia (CML) .

HY-15485

Zardaverine	Phosphodiesterase (PDE) Apoptosis	Inflammation/Immunology Cancer
Zardaverine is an orally active and selective PDE3/4 inhibitor (IC₅₀)=0.58 uM/0.17 uM) with potent bronchodilator activity. Zardaverine also selectively inhibits the proliferation of HCC cells and induces apoptosis and cycle arrest (G0/G1 phase). Zardaverine has good antitumor potential and is effective in both bronchial relaxation and reduction of inflammation in asthma .

HY-114414

HDACs/mTOR Inhibitor 1 1 Publications Verification	HDAC mTOR Apoptosis	Cancer
HDACs/mTOR Inhibitor 1 is a dual HDACs and mTOR inhibitor, with IC₅₀s of 0.19 nM, 1.8 nM, 1.2 nM for HDAC1, HDAC6, mTOR, respectively. HDACs/mTOR Inhibitor 1 stimulates cell cycle arrest in G0/G1 phase and induces tumor cell apoptosis with low toxicity in vivo. HDACs/mTOR Inhibitor 1 can be used in the research of hematologic malignancies .

HY-151630

hCAIX-IN-16	Carbonic Anhydrase	Cancer
hCAIX-IN-16 (Compound 12d) is hCA IX inhibitor, with K_{i values of 190.0 and 187.9 nM for hCA IX and hCA XII, respectively. hCAIX-IN-16 can arrest the cell cycle of breast cancer MDA-MB-468 in G0-G1 and S phase and induce apoptosis. hCAIX-IN-16 shows good broad-spectrum anticancer activity and can be used for cancer research .}

HY-155406

Estrogen receptor modulator 10	Estrogen Receptor/ERR Caspase Bcl-2 Family	Cancer
Estrogen receptor modulator 10 (compound G-5b) is an Estrogen receptor (ER) antagonist (IC₅₀=6.7 nM) and degrader (DC₅₀=0.4 nM). Estrogen receptor modulator 10 can induce apoptosis. Estrogen receptor modulator 10 can block cells at the G1/G0 phase. Estrogen receptor modulator 10 can be used in cancer studies .

Cat. No.	Product Name	Target	Research Area

HY-P10376

Lucicebtide	Peptides	Cancer
Lucicebtide (Compound ST101) is a selective antagonist for CCAAT/enhancer binding protein β (C/EBPβ). Lucicebtide binds to the leucine zipper domain of C/EBPβ, prevents its dimerization, and ubiquitin-dependently degrades C/EBPβ. Lucicebtide arrests cell cycle at G0/G1 phase. Lucicebtide exhibits cytotoxicity in cancer cells. Lucicebtide exhibits good pharmacokinetic characters and inhibits tumor growth in mouse model .

HY-P10376B

Lucicebtide acetate	Peptides	Cancer
Lucicebtide acetate is the acetate salt form of Lucicebtide (HY-P10376). Lucicebtide acetate is a selective antagonist for CCAAT/enhancer binding protein β (C/EBPβ). Lucicebtide acetate binds to the leucine zipper domain of C/EBPβ, prevents its dimerization, and ubiquitin-dependently degrades C/EBPβ. Lucicebtide acetate arrests cell cycle at G0/G1 phase. Lucicebtide acetate exhibits cytotoxicity in cancer cells. Lucicebtide acetate exhibits good pharmacokinetic characters and inhibits tumor growth in mouse model .

Cat. No.	Product Name		Classification

HY-159519

EGFR/HER2-IN-16		Azide
EGFR/HER2-IN-16 (compound 12K) is an effective dual-target inhibitor of EGFR (IC₅₀=6.15 nM) and HER-2 (IC₅₀=9.78 nM) with anti-tumor activity. EGFR/HER2-IN-16 can inhibit the migration of SK-BR-3 cells, arrest the cell cycle in the G0/G1 phase, and induce apoptosis. EGFR/HER2-IN-16 exhibits good anti-proliferative activity against tumor cell models and has little damage to healthy cells. EGFR/HER2-IN-16 can be used in breast cancer research .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

G0/G1 phase

Inhibitors & Agonists

Peptides

NaturalProducts

Click Chemistry

Natural
Products